**PATENTS, GLOBALIZATION, AND PUBLIC HEALTH:  
EFFECTS OF THE WTO TRIPS AGREEMENT ON HIV/AIDS RELATED DEATHS**\*

SAMUEL TROPER  
2013 ½ O ST. NW,  
WASHINGTON, DC 20036

[SAMUEL.TROPER@HOLOCRON.FOUNDATION](mailto:SAMUEL.TROPER@HOLOCRON.FOUNDATION)

1-614-668-0312

**ABSTRACT**

IN THEORY, PATENTS MAY HAVE NEGATIVE EFFECTS. THE IMPLEMENTATION OF A MANDATORY WTO AGREEMENT THAT REQUIRES 20-YEAR PATENT TERMS, THE ESTABLISHMENT OF PHARMACEUTICAL PATENTS AND THE RECOGNITION OF OTHER SIGNATORY’S PATENTS SERVES AS A NATURAL EXPERIMENT THAT OCCURRED SIMULTANEOUS TO THE HIV/AIDS CRISIS. PHARMACEUTICALS PLAY A KEY ROLE IN HIV/AIDS SURVIVAL, SO IF PATENTS HAVE AN EFFECT, WE WOULD EXPECT TO SEE ONE HERE. USING A PANEL DIFFERENCE IN DIFFERENCE REGRESSION, WE FIND AN INCREASE IN HIV/AIDS RELATED DEATHS OF 2.117 PER 10000 UPON THE IMPLEMENTATION OF THE AGREEMENT, SIGNIFICANT BELOW THE 1% LEVEL. ADDITIONALLY, USING INTERACTION TERMS WE FIND EVEN LARGER EFFECTS ON LEAST DEVELOPED COUNTRIES, WHICH SERVE AS A PROXY FOR WEAK PATENT LAWS. THESE RESULTS ARE ALSO SIGNIFICANT AT THE 1% LEVEL. THIS SUGGESTS THE URGENT NEED FOR FURTHER EMPIRICAL STUDIES ON THE EFFECTS OF PATENTS.

JEL CODES: F13, F69, I18, K33, K39, L43, L51, O34

\*I THANK DAVID HARRINGTON FOR SIGNIFICANT CONSTRUCTIVE CRITICISM, ERIC SEIBER AND AMY FERKETICH FOR CONSTRUCTIVE COMMENTS AND INSIGHTS, AND PJ GLANDON FOR MENTORSHIP THROUGHOUT MY CAREER.

# I. INTRODUCTION

In 1995, the World Trade Organization (WTO) adopted an agreement that set minimum standards regarding patent laws in signatory countries. The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) required that signatories recognize patents from other signatories, adopt a patent term of 20 years, and mandates the institution of patents on pharmaceuticals, amongst other requirements. All members of the WTO are required to sign TRIPS, which has led nearly every nation on Earth to adopt patent standards in line with TRIPS. (WTO, 2017) Hence, TRIPS could lead to a decrease in the quantity supplied of patented products including life-saving pharmaceuticals, such as those used in combatting the global HIV/AIDs crisis. This prompts the question of whether TRIPS has triggered an increase in the number of HIV/AIDs related deaths, especially in the poorest countries, which had the weakest patent protections prior to TRIPS.

Simultaneously to the introduction of TRIPS, infections and deaths related to HIV/AIDs were growing globally and the disease became a global priority – leading to some of the most effective measurement of an epidemiological crisis in history. A notable feature of HIV/AIDs is that it can be managed through pharmaceuticals, extending the lifetime and quality of life of an individual indefinitely. Given the effectiveness and usage of pharmaceuticals on HIV/AIDs, policy related to pharmaceuticals would likely influence individuals dealing with this disease, affecting the number of people who die due to this disease.

By looking at the relationship between the HIV/AIDs crisis and the natural experiment TRIPS adoption allows, this paper aims to explore the relationship between patents and high quality quantifiable measure which should be affected.

# II. BACKGROUND AND CURRENT THEORY

Patents serve to protect disclosed intellectual property. They provide a mechanism for an inventor to disclose the design of an invention in return for time-limited monopolistic rights to said item or process. In theory, there are positive and negative aspects of patents.

Some theory paints a positive picture of the effects of patents. Patents may spur the development of new inventions. Disclosing an invention allows others to observe its invention and to license the use of said invention if an agreement is made with a patent holder. This encourages the spread of knowledge. Additionally, disclosure could allow others to innovate further on the item which was publicly disclosed. Others could find novel uses for inventions that have been publicly disclosed.

Patents may also encourage higher investment in innovation. Patents allow the monopolization of an item for 20 years, which can lead to profits which could be used to recoup investment costs. This increases the incentive to innovate, leading to inventions which would not have otherwise been pursued. This is particularly relevant to pharmaceuticals, as the price of research is extremely high. Having a patent may also increase availability and marketing for patented products because of the artificial monopoly.

Patents may also have negative effects. The standard model of a monopoly suggests that the price and quantity that will occur are not efficient. Besides the abstract deadweight loss, this can be thought about in more concrete terms. A lower than optimal availability of life-saving drugs could lead to deaths. Gold et al. (2009) find that patents do increase the cost of pharmaceuticals in high, middle, and low-income countries.

The benefits of increased knowledge may be offset by the long length of time that patents last for. This could also hamper any innovation that builds upon inventions that have been patented, as many new inventions contain hundreds of parts which each may be patented. This makes innovation build upon prior work extremely difficult. Creating an invention may involve untangling a legal webwork of prior patents.

Very simple inventions – inventions as simple as 1-click checkout (Dewitt, 2017) – may be patented, which could reduce the usage of certain inventions well below the optimal level. Hall and Harhoff (2012) state that “firms and individuals that are endowed with such a rather complex legal instrument will learn to use it strategically in ways that may not serve the intent of the legislation that created the instrument.” Between patenting trivial ideas and taking advantage of regulatory framework, inefficiencies may arise.

TRIPS creates a global framework for patents. We would expect to observe some results related to some or all the theories above as well. Kyle and McGahan (2009) find that the TRIPS agreement and patents led to more innovation in developed countries, but not in the poorest countries. They also found that most corporations focused on research for wealthier countries since the highest profits could be found in those countries.

# III. DATA

Data was collected from several public sources. As a proxy for patent strength in a country, the date that TRIPS came into force for a given country was taken from the World Intellectual Property Organization. The number of AIDs related deaths by country by year was taken from UNAIDS AIDSInfo. This was combined with population by country, which was taken from The World Bank, to create a measure of HIV/AIDs-related deaths per 10000. In several instances, a range containing upper and lower bounds was given for HIV/AIDs-related deaths, as well as an estimate. In these instances, the estimate was used. Any country without data on deaths or population in a single year was dropped from this analysis. This leaves us with 3348 observations from 124 countries across the years 1995 to 2016, inclusive. Country classifications were taken from two sources. Least developed countries (LDCs) were taken from the WTO. Developing countries (DCs) were taken from Deere (2009).

Table I presents the mean and standard deviations for HIV/AIDs-related deaths per 10000. Figure I was constructed by averaging HIV/AIDs-related deaths per 10000 by country category by year. Table I and Figure I tell a relatively straightforward story: HIV/AIDs had the largest impact in LDCs, and a smaller impact on developed countries. Additionally, the HIV/AIDs crisis slowly got worse before getting better. This trend holds both of the aggregated data and when the data is divided by country category.

Figure II presents the changes in adoption of TRIPS over time, by country category. Initially, TRIPS was adopted in 73 countries in 1995. This is 58% of the countries within the data set. By the end of 2016, 111 countries within the data set had TRIPS in force. This is 89% of the countries within the data set. Adoption by DCs was done by 2000,[[1]](#footnote-1) while developed and LDCs adopted more gradually over time following the high number of initial adopters in these categories. This is displayed in Figure II.

By comparing Figure I to Figure II, we would might expect to see some evidence of TRIPS influencing HIV/AIDs related deaths. A cursory glance indicates that this isn’t the case. It is possible that the HIV/AIDs crisis is severe enough that any change due to implementation of TRIPS is small relative to the changes due to the spread of the disease and efforts by nations and international bodies to combat the disease. This would indicate that there may be other omitted variable affecting the spread of HIV/AIDs.

To look more closely at the effect of TRIPS on HIV/AIDs related deaths, Figure III presents the mean deaths\_per\_10000 using the time before/after TRIPS was implemented instead of year. One might expect to see a sharp increase immediately or shortly after TRIPS implementation and a steeper slope following the implementation. This is not immediately clear from the figure, likely due to similar reasons mentioned in the previous paragraph occurring frequently after the implementation of TRIPS. A regression may be more effective at picking up any potential effects of TRIPS.

# IV. MODEL AND RESULTS

A panel regression with interaction terms was performed. The specification is as follows:

is HIV/AIDs-related deaths per 10000 in country in year . is a dummy variable which is 1 if country has joined the TRIPS agreement in year and is also referred to as TRIPS in force. is a dummy variable which is 1 if country is a LDC, and is a dummy variable which is 1 if country is a DC. Interaction terms using and both and were also used. and represent year and country fixed effects, respectively. Country fixed effects allow for country specific effects to be considered, such as a high initial prevalence of HIV/AIDs in a country. Year fixed effects will consider global factors of the disease, such as efforts by international bodies to combat the disease. The results of this regression are presented in Table II. Note that either the LDC and DC dummy variables were used, or country fixed effects were used, as the country classifications attempt to capture the same factors that would be measured by a country fixed effect.

Under all specifications used with this model, TRIPS in force has very significant positive coefficients. In the model using interaction terms, countries which had TRIPS in force experienced 4.014 more deaths per 10000 than a country that didn’t, a result which is significant at the 1% level. Given that the mean number of deaths per 10000 is 2.565 across all observations when TRIPS was not in force, implementing TRIPS is expected to increase HIV/AIDs related deaths by 156%. This result is in line with the theoretical impact as well: granting a monopoly for a lifesaving drug would reduce the quantity of life-saving medication sold and as a result increase deaths related to HIV/AIDs.

Another key result revolves around the interaction terms LDCxTRIPS in force. The coefficient means that LDCs experience an additional 3.582 deaths per 10000 when TRIPS was in forace as compared to a developed country. This result is significant at the 1% level. This means that an LDC which has implemented TRIPS experiences 7.596 more HIV/AIDs related deaths relative to another LDC which has not implemented TRIPS. This number is even higher when compared to DCs or DEV. The equations needed to derive this result follow below.

In least developed countries, where the average number of HIV/AIDs related deaths per 10000 is 4.276 in years in which TRIPS was not implemented, we would expect to see a 177% increase in HIV/AIDs related deaths due to TRIPS implementation. Theory supports this outcome: Most developed countries already had strong patent systems in place prior to TRIPS, while many LDCs did not. This would mean that TRIPS would disproportionately affect LDCs. In essence, LDC can be thought of as a proxy for a weak initial patent system. It is also notable that switching between using country fixed effects and dummy variables for LDCs and DCs changes the coefficients but doesn’t change the sign or the significance category a result falls into.

The HIV/AIDs crisis and patent laws are both complex items that have many factors affecting them. This leads to a possibility of omitted variables. One key omitted variable is the issuance of compulsory licenses. TRIPS contained a provision allowing the licensing of drugs for crises. This was provided to potentially offset the negative effects of patents. A regression using a dummy variable for compulsory licenses was also performed. Instances of compulsory licensing were taken from Beall and Kuhn (2012). A dummy variable was created, called compulsory license. This variable is 1 in a country and year when a compulsory license was issued for HIV/AIDs related drugs. The results of that regression are presented in Table III. Note that this data only reflects instances of compulsory licensing prior to 2011, and that the corresponding regression was only performed on data from 2011 an prior.

In theory, it would be expected that compulsory licenses would reduce HIV/AIDs related deaths by making pharmaceuticals more available. Additionally, it would also be expected to decrease the value of TRIPS in force, since the most severe instances of HIV/AIDs outbreaks would be addressed by a compulsory license. Only one regression found a significant coefficient for compulsory licenses. While this mechanism may work in theory to reduce the negative effect of increased patent protection, the results of the regression do not support that, potentially because of the correlation of a spike in HIV/AIDs and the likelihood a country would issue a compulsory license. Additionally, there were only 19 country-year instances where compulsory licenses were issued in 1990-2010, indicating that the tool is rarely used.

One might observe that HIV/AIDs was increasing over the years, particularly in 1995 when many countries signed onto TRIPS. This increase may be correlated with TRIPS in force, even though it was already occurring prior to TRIPS. Running the same regression with all years prior to 2005 removed from the sample results in coefficients of similar values and significance to earlier regressions, indicating that this upward trend from 1990 to 2004 wasn’t being captured by the TRIPS in force variable in prior regressions. The results are presented in Table IV.

# V. FUTURE WORK

One key way to improve the results of this paper would be to find the exact dates TRIPS related laws went into effect in a country. Currently, the date that a country joined TRIPS is included in this paper – but the exact dates that these reforms were implemented would paint a more accurate picture. This task would be difficult, as it would involve acquiring and reading through patent laws – historical and modern – for most of the globe, in a variety of languages.

An alternative mechanism which could provide even more accurate regressions would be acquiring the length of the term of patents by country by year. This would involve a similar process to the above but would require even more details from said patents broken out by year and a keen attention to detail in the local laws of a variety of countries. Creating such a data set, however, could be invaluable to future analyses regarding patent effectiveness.

The HIV/AIDs crisis is a complex event and there may be omitted variables. Other variables should be found and incorporated. These additional variables may include price controls and other mechanisms which countries can use under TRIPS to reduce the price of pharmaceuticals.[[2]](#footnote-2) Incorporating the effect of patents into epidemiological papers regarding the HIV/AIDs crisis may also serve a similar function.

Similar research on other diseases or other measures which may be heavily influenced by patents could be done to verify these effects using similar methods to this study. Research could also be done in a different area of the economy to get further insight into the effects of the TRIPS agreement and patents on the more general economy.

# VI. CONCLUSION

The results of regressions used within this paper suggest TRIPS introduction is highly correlated to deaths due to HIV/AIDs. The use of a difference in difference regression combined with the natural experiment of the TRIPS agreement provides stronger – but not conclusive – evidence of causality. This lines up with the negative theories regarding patents and more broadly monopolies. The granting of monopolistic rights for a patent would reduce the quantity sold of an item, and if that item is a lifesaving item, it may increase deaths. Additionally, TRIPS seems to have disproportionately affected LDCs, which is a similar conclusion that Gold et al found in their work as well. LDCs may be seen as a proxy for weak patent laws, further suggesting the potential damage stringent patent laws may cause.

While the results of this paper seem to paint a negative portrait of patents, more research into the area would be needed to be more conclusive. Instead of using TRIPS as a proxy for patent strength, finding individual, country level patent information would provide a stronger explanatory variable. Additionally, the HIV/AIDs crisis is very complex, and additional omitted variables are something that should be further addressed.

# APPENDIX A1: FIGURES

# APPENDIX A2: TABLES

**Table I**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | **All Countries** | | **LDCs** | **DCs** | | **Developed Countries** | |
| **HIV/AIDs-related deaths per 10000** | **1995-2016** | | 5.773  (12.239) | | 9.109  (13.740) | 5.841  (12.551) | | 4.005  (10.777) | |
| **1995** | | 4.248  (9.300) | | 7.376  (12.369) | 4.245  (9.869) | | 3.010  (6.509) | |
| **2005** | | 8.869  (17.350) | | 13.632  (18.756) | 9.622  (18.216) | | 5.937  (15.678) | |
| **2015** | | 3.926  (6.662) | | 6.413  (9.292) | 3.632  (5.686) | | 2.821  (5.237) | |
| **Total Number of Countries** | | | 124 | | 30 | 36 | | 58 | |
| Note: Means and standard deviations presented. Standard deviations are in parentheses.  **Table II: Regression Results** | | | | | | | | | |
|  | | **HIV/AIDs-related deaths per 10000** | | | | | | |
| **TRIPS in force** | | 2.117\*\*\*  [.486] | | 4.961\*\*\*  [.594] | | | 4.014\*\*\*  [.677] | |
| **DC** | |  | | .669  [.501] | | | .004  [.977] | |
| **DCxTRIPS in force** | |  | |  | | | 1.140  [1.140] | |
| **LDC** | |  | | 4.404\*\*\*  [.517] | | | 2.079\*\*  [.873] | |
| **LDCxTRIPS in force** | |  | |  | | | 3.582\*\*\*  [1.084] | |
| **Country Fixed Effects** | | Yes | | No | | | No | |
| **Year Fixed Effects** | | Yes | | Yes | | | Yes | |

\*\*\*- significant at the 1% level \*\* - significant at the 5% level \* - significant at the 10% level  
Standard errors are contained in brackets. Data is from 124 countries from 1990 to 2016, inclusive, resulting in 3224 observations.

**Table III: Regression Results, with Compulsory Licenses**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **HIV/AIDs-related deaths per 10000** | | |
| **TRIPS in force** | 2.171781\*\*\*  [.5344734] | 5.74884\*\*\*  [.7229842] | 4.663023\*\*\*  [.8358431] |
| **Compulsory License** | 2.024914  [1.546565] | 4.889376  [2.990102] | 4.969208\*  [2.99637] |
| **DC** |  | .5423498  [.6224861] | .1274091  [1.081929] |
| **DCxTRIPS in force** |  |  | .942453  [1.32513] |
| **LDC** |  | 4.661789\*\*\*  [.6357835] | 2.315978\*\*  [.9823342] |
| **LDCxTRIPS in force** |  |  | 4.024603\*\*\*  [1.288404] |
| **Country Fixed Effects** | Yes | No | No |
| **Year Fixed Effects** | Yes | Yes | Yes |

\*\*\*- significant at the 1% level \*\* - significant at the 5% level \* - significant at the 10% level  
Standard errors are contained in brackets. Data is from 124 countries from 1990 to 2010, inclusive, resulting in 2480 observations.

**Table IV: Robustness Regression**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **HIV/AIDs-related deaths per 10000** | | |
| **TRIPS in force** | 2.581\*\*\*  [.987] | 3.324\*\*\*  [.811] | 2.399\*\*\*  [.901] |
| **DC** |  | 1.196\*  [.687] | 1.406  [.692] |
| **DCxTRIPS in force** |  |  | See note |
| **LDC** |  | 4.596\*\*\*  [.711] | .4799274  [1.900] |
| **LDCxTRIPS in force** |  |  | 4.767\*\*  [2.041] |
| **Country Fixed Effects** | Yes | No | No |
| **Year Fixed Effects** | Yes | Yes | Yes |

\*\*\*- significant at the 1% level \*\* - significant at the 5% level \* - significant at the 10% level  
Standard errors are contained in brackets. Data is from 124 countries from 2005 to 2016, inclusive, resulting in 1488 observations.  
Note: Since all DCs except one implemented TRIPS prior to 2005, this variable would capture nearly the same information as DC. As such, it has been left out of the regression.

# REFERENCES

Beall, Reed, and Randall Kuhn, "Trends in Compulsory Licensing of Pharmaceuticals Since the Doha Declaration: A Database Analysis," PLOS Medicine, January 10, 2012. Accessed November 13, 2017. Available at http://journals.plos.org/plosmedicine/article?id=10.1371%2Fjournal.pmed.1001154.

WIPO. Accessed November 13, 2017. Available at http://www.wipo.int/portal/en/.

"AIDSinfo," AIDSinfo | UNAIDS. Accessed November 13, 2017. Available at http://aidsinfo.unaids.org/.

Deere, Carolyn, "The Implementation Game: The TRIPS Agreement and the Global Politics of Intellectual Property Reform in Developing Countries," Oxford Scholarship Online, May 2009. Accessed November 13, 2017.

Dewitt, Julia, "Amazon's 1-Click Patent Is About To Expire. What's The Big Deal?" NPR, September 06, 2017. Accessed November 13, 2017. Available at https://www.npr.org/2017/09/06/548819270/amazon-s-1-click-patent-is-about-to-expire-what-s-the-big-deal.

Gold, E. Richard et al., "Are Patents Impeding Medical Care and Innovation?" January 2009. Accessed November 13, 2017. Available at http://apps.who.int/medicinedocs/documents/s17581en/s17581en.pdf.

Hall, Bronwyn H., and Dietmar Harhoff. "Recent Research on the Economics of Patents," January 2012. Accessed November 13, 2017. Available at http://www.nber.org/papers/w17773.pdf.

Kyle, Margaret, and Anita McGahan. "Investments in Pharmaceuticals Before and After TRIPS," October 2009. Accessed November 13, 2017. Available at http://www.nber.org/papers/w15468.pdf.

"Population, total," World Bank. Accessed November 13, 2017. Available at https://data.worldbank.org/indicator/SP.POP.TOTL.

"Understanding the WTO - least-developed countries," WTO. Accessed November 13, 2017. Available at https://www.wto.org/english/thewto\_e/whatis\_e/tif\_e/org7\_e.htm.

"Members and Observers," WTO. Accessed November 13, 2017. Available at https://www.wto.org/english/thewto\_e/whatis\_e/tif\_e/org6\_e.htm.

1. DCs were a special category of country created for early adoption of WTO agreements by countries which did not fall into the UN’s LDC category but had cofounding factors that put them at a disadvantage in treaty adoption compared to a significant subset of developed countries. Once the early adoption period of the WTO ceased, countries would either be categorized as DEV countries or LDCs, since the advantages provided to DCs ceased. [↑](#footnote-ref-1)
2. Compulsory licensing is only one such tool, but it is the most explicitly defined and studied. [↑](#footnote-ref-2)